IPO Filing Floodgates: Aegerion Pharmaceuticals, Inc. (AEGR)

Health and Healthcare

Published: November 21, 2007 12:55 pm

Last Updated: March 26, 2020 12:13 pm

Aegerion Pharmaceuticals, Inc. filed Tuesday for an initial public offering of up to $86.25 million in securities for filing purposes. It has the proposed ticker of "AEGR" on NASDAQ, and the underwriting group consists of Piper Jaffray, Thomas Weisel partners, Lazard Capital Markets, and Collins Stewart, LLC.

Aegerion is an emerging biotech company focused on small-molecule therapeutics to treat cardiovascular and metabolic disease. Its lead product candidates, AEGR-733 and AEGR-427, are microsomal triglyceride transfer protein inhibitors, or MTP-Is, which limit secretion of cholesterol and triglycerides from both the intestine and liver.

24/7 Wall St. will have to do some research here because this IPO had originally been filed back in March 2007, but was withdrawn from registration in June.

If you wish to join our open email distribution list we often provide more detailed IPO and spin-off coverage. These are frequently lead-ins to our subscriber-based "Special Situation Investing Newsletter" where we cover buyouts, spin-offs, back-door plays into IPO’s, reorganizations, and more.

Jon C. Ogg
November 21, 2007

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: are you ahead, or behind on your retirement goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With SmartAsset’s free tool, you can connect with vetted financial advisors in minutes.

Why wait? Click here to get started today!